High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer
Jie Mei(Sun Yat-sen University), Yongmei Yin(Nanjing Medical University), Wenjun Mao(Wuxi People's Hospital), Junying Xu(Wuxi People's Hospital), Ziyi Fu, Chenghu Song(Wuxi People's Hospital), Ying Jiang(Soochow University), Kai Yang(Harbin Medical University), Jinlu Zhao(Harbin Medical University), Lingyan Chen, Yan Zhang(Wuhan University), Hongjun Zhu(Nantong University), Yun Cai(Jiangsu University)
Cited by 36
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
The role of lipid metabolic reprogramming in tumor microenvironment
|Theranostics|2023|223
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
|Cancer Discovery|2022|137
Comprehensive analysis of prognostic immune‐related genes in the tumor microenvironment of cutaneous melanoma
|Journal of Cellular Physiology|2019|111